RespireRx Pharmaceuticals Management
Management criteria checks 3/4
RespireRx Pharmaceuticals' CEO is Arnold Lippa, appointed in Aug 2015, has a tenure of 9.42 years. directly owns 1.21% of the company’s shares, worth $9.17K. The average tenure of the management team and the board of directors is 10.3 years and 10.3 years respectively.
Key information
Arnold Lippa
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 9.4yrs |
| CEO ownership | 1.2% |
| Management average tenure | 10.3yrs |
| Board average tenure | 10.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$4m |
| Dec 31 2022 | US$340k | US$340k | -US$4m |
| Sep 30 2022 | n/a | n/a | -US$4m |
| Jun 30 2022 | n/a | n/a | -US$4m |
| Mar 31 2022 | n/a | n/a | -US$4m |
| Dec 31 2021 | US$340k | US$340k | -US$4m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | US$340k | US$340k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$3m |
| Mar 31 2020 | n/a | n/a | -US$3m |
| Dec 31 2019 | US$340k | US$340k | -US$2m |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | n/a | n/a | -US$2m |
| Mar 31 2019 | n/a | n/a | -US$2m |
| Dec 31 2018 | US$340k | US$340k | -US$3m |
Compensation vs Market: Insufficient data to establish whether Arnold's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Arnold's compensation has been consistent with company performance over the past year.
CEO
Arnold Lippa (77 yo)
9.4yrs
Tenure
US$339,600
Compensation
Dr. Arnold S. Lippa, Ph D., has been an Executive Chairman of RespireRx Pharmaceuticals Inc., since March 22, 2013 and its Chief Scientific Officer since August 19, 2015 and has been its Interim President...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 9.4yrs | US$339.60k | 1.21% $ 9.2k | |
| Senior VP | 11.8yrs | US$321.60k | 1.12% $ 8.5k | |
| Senior Vice President of Research & Development | 10.3yrs | US$199.86k | 0.000060% $ 0.5 | |
| Senior Vice President of Pre-Clinical Product Development | 4.3yrs | no data | 0% $ 0 | |
| Controller | 11.6yrs | no data | 0.22% $ 1.7k |
10.3yrs
Average Tenure
65.5yo
Average Age
Experienced Management: RSPI's management team is seasoned and experienced (10.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 11.8yrs | US$339.60k | 1.21% $ 9.2k | |
| Senior VP | 11.8yrs | US$321.60k | 1.12% $ 8.5k | |
| Independent Director | 1.8yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 10.3yrs | no data | no data | |
| Director | less than a year | no data | no data |
10.3yrs
Average Tenure
76yo
Average Age
Experienced Board: RSPI's board of directors are seasoned and experienced ( 10.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 15:54 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RespireRx Pharmaceuticals Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| J. McCarthy | NOBLE Capital Markets, Inc. |